# Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

> **NCT06596252** · PHASE3 · RECRUITING · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 308 (estimated)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT06596252
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-21
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06596252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06596252, "Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06596252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*